Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding... | May 3, 2023
Sri Lanka Queen Elizabeth Newron Pharmaceuticals Schizophrenia International Research Society Ongoing International Randomized Study World Congress
Source: marketscreener.com